Libtayo (cemiplimab-rwlc) Injection, 350 mg/7 mL (50 mg/mL), For Intravenous Infusion After Dilution, Single-Dose Vial, Rx only, Manufactured by: Regeneron Pharmaceuticals, Inc., Tarrytown, NY 10591; Marketed by: Regeneron Pharmaceuticals, Inc. (Tarrytown, NY 10591), NDC 61755-008-01

Recall Number: D-0767-2026

Firm: Regeneron Pharmaceuticals Inc

Classification: Class II

Status: Ongoing

Report Date: 20260826

Initiation Date: 20260728

Termination Date:

Reason for Recall

Lack of Assurance of Sterility

Product Description

Libtayo (cemiplimab-rwlc) Injection, 350 mg/7 mL (50 mg/mL), For Intravenous Infusion After Dilution, Single-Dose Vial, Rx only, Manufactured by: Regeneron Pharmaceuticals, Inc., Tarrytown, NY 10591; Marketed by: Regeneron Pharmaceuticals, Inc. (Tarrytown, NY 10591), NDC 61755-008-01

DrugLabelsHub provides FDA drug labeling information for reference only. Always consult a healthcare professional.

Data source: openFDA · Updated regularly